vs

Side-by-side financial comparison of Sprinklr, Inc. (CXM) and NEOGEN CORP (NEOG). Click either name above to swap in a different company.

NEOGEN CORP is the larger business by last-quarter revenue ($224.7M vs $219.1M, roughly 1.0× Sprinklr, Inc.). Sprinklr, Inc. runs the higher net margin — 1.3% vs -7.1%, a 8.4% gap on every dollar of revenue. On growth, Sprinklr, Inc. posted the faster year-over-year revenue change (9.2% vs -2.8%). Sprinklr, Inc. produced more free cash flow last quarter ($19.8M vs $7.8M). Over the past eight quarters, Sprinklr, Inc.'s revenue compounded faster (6.2% CAGR vs -0.9%).

Sprinklr is an American software company that develops a software as a service (SaaS) customer experience management (CXM) platform. The company's software, also called Sprinklr, combines different applications for social media marketing, social advertising, content management, collaboration, employee advocacy, customer care, social media research, and social media monitoring.

Neogen Corporation is an international food safety company that provides test kits and relevant products to detect dangerous substances in food. The company was founded in 1982 and is based in Lansing, Michigan. The company serves a wide range of countries including Canada, United States, the United Kingdom, parts of Europe, Mexico and Brazil, India, and China, among others. The company operates a product line of over 100 drug detection test kits worldwide for the detection of about 300 abuse...

CXM vs NEOG — Head-to-Head

Bigger by revenue
NEOG
NEOG
1.0× larger
NEOG
$224.7M
$219.1M
CXM
Growing faster (revenue YoY)
CXM
CXM
+12.0% gap
CXM
9.2%
-2.8%
NEOG
Higher net margin
CXM
CXM
8.4% more per $
CXM
1.3%
-7.1%
NEOG
More free cash flow
CXM
CXM
$12.0M more FCF
CXM
$19.8M
$7.8M
NEOG
Faster 2-yr revenue CAGR
CXM
CXM
Annualised
CXM
6.2%
-0.9%
NEOG

Income Statement — Q3 FY2026 vs Q2 FY2026

Metric
CXM
CXM
NEOG
NEOG
Revenue
$219.1M
$224.7M
Net Profit
$2.9M
$-15.9M
Gross Margin
66.4%
47.5%
Operating Margin
5.3%
-2.4%
Net Margin
1.3%
-7.1%
Revenue YoY
9.2%
-2.8%
Net Profit YoY
-72.2%
96.5%
EPS (diluted)
$0.01
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CXM
CXM
NEOG
NEOG
Q4 25
$219.1M
$224.7M
Q3 25
$212.0M
$209.2M
Q2 25
$205.5M
$225.4M
Q1 25
$202.5M
$221.0M
Q4 24
$200.7M
$231.3M
Q3 24
$197.2M
$217.0M
Q2 24
$196.0M
$236.8M
Q1 24
$194.2M
$228.8M
Net Profit
CXM
CXM
NEOG
NEOG
Q4 25
$2.9M
$-15.9M
Q3 25
$12.6M
$36.3M
Q2 25
$-1.6M
$-612.3M
Q1 25
$98.7M
$-10.9M
Q4 24
$10.5M
$-456.3M
Q3 24
$1.8M
$-12.6M
Q2 24
$10.6M
$-5.4M
Q1 24
$21.1M
$-2.0M
Gross Margin
CXM
CXM
NEOG
NEOG
Q4 25
66.4%
47.5%
Q3 25
68.2%
45.4%
Q2 25
69.5%
41.2%
Q1 25
71.0%
49.9%
Q4 24
71.2%
49.0%
Q3 24
72.6%
48.4%
Q2 24
73.9%
47.9%
Q1 24
75.5%
51.1%
Operating Margin
CXM
CXM
NEOG
NEOG
Q4 25
5.3%
-2.4%
Q3 25
7.7%
-7.7%
Q2 25
-0.9%
-271.1%
Q1 25
5.2%
2.4%
Q4 24
3.9%
-197.8%
Q3 24
-0.0%
1.0%
Q2 24
2.9%
5.5%
Q1 24
9.5%
5.3%
Net Margin
CXM
CXM
NEOG
NEOG
Q4 25
1.3%
-7.1%
Q3 25
5.9%
17.4%
Q2 25
-0.8%
-271.6%
Q1 25
48.7%
-4.9%
Q4 24
5.2%
-197.3%
Q3 24
0.9%
-5.8%
Q2 24
5.4%
-2.3%
Q1 24
10.9%
-0.9%
EPS (diluted)
CXM
CXM
NEOG
NEOG
Q4 25
$0.01
$-0.07
Q3 25
$0.05
$0.17
Q2 25
$-0.01
$-2.82
Q1 25
$0.35
$-0.05
Q4 24
$0.04
$-2.10
Q3 24
$0.01
$-0.06
Q2 24
$0.04
$-0.02
Q1 24
$0.07
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CXM
CXM
NEOG
NEOG
Cash + ST InvestmentsLiquidity on hand
$189.6M
$145.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$558.1M
$2.1B
Total Assets
$1.1B
$3.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CXM
CXM
NEOG
NEOG
Q4 25
$189.6M
$145.3M
Q3 25
$125.4M
$138.9M
Q2 25
$126.4M
$129.0M
Q1 25
$145.3M
$127.7M
Q4 24
$93.2M
$140.2M
Q3 24
$119.1M
$120.5M
Q2 24
$126.8M
$170.9M
Q1 24
$164.0M
$168.4M
Stockholders' Equity
CXM
CXM
NEOG
NEOG
Q4 25
$558.1M
$2.1B
Q3 25
$543.4M
$2.1B
Q2 25
$639.8M
$2.1B
Q1 25
$612.1M
$2.7B
Q4 24
$497.0M
$2.7B
Q3 24
$469.0M
$3.1B
Q2 24
$610.9M
$3.1B
Q1 24
$679.7M
$3.1B
Total Assets
CXM
CXM
NEOG
NEOG
Q4 25
$1.1B
$3.4B
Q3 25
$1.1B
$3.4B
Q2 25
$1.2B
$3.4B
Q1 25
$1.2B
$4.0B
Q4 24
$970.3M
$4.1B
Q3 24
$983.8M
$4.5B
Q2 24
$1.1B
$4.5B
Q1 24
$1.2B
$4.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CXM
CXM
NEOG
NEOG
Operating Cash FlowLast quarter
$20.0M
$19.4M
Free Cash FlowOCF − Capex
$19.8M
$7.8M
FCF MarginFCF / Revenue
9.0%
3.5%
Capex IntensityCapex / Revenue
0.1%
5.2%
Cash ConversionOCF / Net Profit
6.87×
TTM Free Cash FlowTrailing 4 quarters
$142.3M
$-18.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CXM
CXM
NEOG
NEOG
Q4 25
$20.0M
$19.4M
Q3 25
$34.8M
$10.9M
Q2 25
$83.8M
$16.4M
Q1 25
$5.4M
$19.5M
Q4 24
$9.2M
$40.3M
Q3 24
$21.3M
$-17.9M
Q2 24
$41.7M
$26.7M
Q1 24
$17.3M
$-30.2M
Free Cash Flow
CXM
CXM
NEOG
NEOG
Q4 25
$19.8M
$7.8M
Q3 25
$34.4M
$-13.1M
Q2 25
$83.5M
$349.0K
Q1 25
$4.6M
$-13.4M
Q4 24
$8.2M
$23.1M
Q3 24
$19.8M
$-56.3M
Q2 24
$39.2M
$2.5M
Q1 24
$15.2M
$-62.3M
FCF Margin
CXM
CXM
NEOG
NEOG
Q4 25
9.0%
3.5%
Q3 25
16.2%
-6.3%
Q2 25
40.6%
0.2%
Q1 25
2.3%
-6.1%
Q4 24
4.1%
10.0%
Q3 24
10.1%
-26.0%
Q2 24
20.0%
1.1%
Q1 24
7.9%
-27.2%
Capex Intensity
CXM
CXM
NEOG
NEOG
Q4 25
0.1%
5.2%
Q3 25
0.2%
11.5%
Q2 25
0.1%
7.1%
Q1 25
0.4%
14.9%
Q4 24
0.5%
7.4%
Q3 24
0.8%
17.7%
Q2 24
1.3%
10.2%
Q1 24
1.1%
14.0%
Cash Conversion
CXM
CXM
NEOG
NEOG
Q4 25
6.87×
Q3 25
2.76×
0.30×
Q2 25
Q1 25
0.05×
Q4 24
0.88×
Q3 24
11.58×
Q2 24
3.92×
Q1 24
0.82×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CXM
CXM

License And Service$190.3M87%
Professional Services$28.8M13%

NEOG
NEOG

Other$109.2M49%
Bacterial And General Sanitation$44.9M20%
Services$25.7M11%
Natural Toxins And Allergens$20.4M9%
Animal Care$8.9M4%
Genomics Services$6.3M3%
Biosecurity Products$4.6M2%
Life Sciences$1.4M1%

Related Comparisons